My end of year review of GERN
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
Geron
GERN
(market cap ~$0.35B)
Geron is the most leading edge biotech I can think of. Nuclear cell transfer, telormase (sp?) modification, stem cells, basically, cloning and the ability to kill cells (cancer), sustain them (prolong life), or grow them (organ replacement, repair, or even nerve regeneration) means that if Geron's technologies are successful, life as we know it will change. Big enough dreams for you?
They are still a highly speculative company and stock, though more tangible because clinical trials have begun. Despite that they have many years between now and an FDA approved treatment. Of course, they may also create amazing and historic benefits to our species.
In the meantime, they may generate licensing revenues, which can be sustaining. Management seems to be very competent and patient.
I will continue to HOLD, may have to SELL to pay some bills, and would consider it a candidate to BUY if I had sufficient discretionary funds, but I'd probably shop for companies that have closer product launches.
DISCLAIMER LTBH since 1999. |
